Treatment

To protect access for people with type 2 diabetes, the Province of British Columbia is limiting the sale of the medications tirzepatide (Mounjaro), dulaglutide (Trulicity), and semaglutide (Ozempic, Wegovy, Rybelsus).

These drugs are being increasingly used off-label for weight loss, contributing to shortages. Under updated regulations, B.C. pharmacies can only sell these medications to B.C. residents, Canadian citizens, or permanent residents. Non-Canadians may purchase them only in person and with a valid prescription from a Canadian healthcare provider.

news.gov.bc.ca

The Province is limiting sales of the drugs tirzepatide and dulaglutide, commonly known by the brand names Mounjaro and Trulicity, to preserve the supply for people with diabetes who really need it.